Correction to: Scientific Reports https://doi.org/10.1038/s41598-019-48593-4, published online 19 August 2019
This Article contained errors in Tables 1, 3 and 4 due to incorrectly written code.
In Table 1, the totals reported for PS 0-1/2-4, mMRC 0-1/2-4 and GAP index 1-5/6-9 under the subheading “Present study n = 77”, are incorrect.
The correct totals should read 55/22, 52/25 and 46/31 respectively.
As a result, in the Results section under the subheading ‘Patients characteristics’,
“The median age was 71 (range: 46–88) years. There were 12 (15.6%) women, 11 (14.3%) non-smokers, and 24 (31.2%) patients with a poor PS (2–4). The mean BMI was 22.9 ± 0.72 kg/m2.”
should read:
“The median age was 71 (range: 46–88) years. There were 12 (15.6%) women, 11 (14.3%) non-smokers, and 22 (28.6%) patients with a poor PS (2–4). The mean BMI was 22.7 ± 3.95 kg/m2.”
In Table 3, the totals reported for BMI < 21.6 and BMI ≥ 21.6 are incorrect.
The correct totals should read 25, 12, 13 and 52, 40, 12 respectively.
In Table 4, the totals reported for PS 0-1/2-4, BMI < 21.6, BMI ≥ 21.6 and Nintedanib dose for 300 mg/day and 200 mg/day are incorrect.
The correct totals should read 55, 39, 16 and 22, 11, 11 and 25, 10, 15 and 52, 40, 12 and 51, 34, 17 and 26, 16, 10 respectively.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kato, M., Sasaki, S., Nakamura, T. et al. Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep 10, 12080 (2020). https://doi.org/10.1038/s41598-020-69088-7
Published:
DOI: https://doi.org/10.1038/s41598-020-69088-7
This article is cited by
-
Clinical significance of high monocyte counts for the continuous treatment with nintedanib
BMC Pulmonary Medicine (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
